HCV E1E2-MF59 vaccine in chronic hepatitis C patients treated with PEG-IFN&#945;2a and Ribavirin: a randomized controlled trial. by Almasio, P. et al.
HCV E1E2-MF59 vaccine in chronic hepatitis C patients
treated with PEG-IFNa2a and Ribavirin: a randomized
controlled trial
P. Colombatto,1 M. R. Brunetto,1 A. M. Maina,1 V. Romagnoli,1 P. Almasio,2 M. G. Rumi,3
A. Ascione,4 G. Pinzello,5 M. Mondelli,6 L. Muratori,7 R. Rappuoli,8 D. Rosa,8
M. Houghton,9 S. Abrignani10 and F. Bonino11* 1Hepatology Unit, University Hospital of Pisa, Pisa, Italy; 2Sezione di
Gastroenterologia, Di.Bi.M.I.S., University of Palermo, Palermo, Italy; 31st Gastroentrology Unit ‘Ca Granda’- IRCCS Foundation, University of
Milano, Milano, Italy; 4Liver Unit, Cardarelli Hospital, Napoli, Italy; 5Medical Department, Niguarda Hospital, Milano, Italy; 6Department of
Infectious Diseases, University of Pavia, Pavia, Italy; 7Department of Clinical Medicine, ‘S.Orsola-Malpighi’ University Hospital of Bologna, Bologna,
Italy; 8Novartis, Siena, Italy; 9Canada Excellence Research Chair in Virology University of Alberta, Edmonton, AB, Canada; 10National Institute of
Molecular Genetics (INGM), Milano, Italy; and 11Liver and Digestive Division, General Medicine 2 Unit, University Hospital of Pisa, Pisa, Italy
Received December 2012; accepted for publication June 2013
SUMMARY. Hepatitis C virus (HCV) vaccines may be able to
increase viral clearance in combination with antiviral ther-
apy. We analysed viral dynamics and HCV-specific immune
response during retreatment for experienced patients in a
phase Ib study with E1E2MF59 vaccine. Seventy-eight
genotype 1a/1b patients [relapsers (30), partial responders
(16) and nonresponders (32) to interferon-(IFN)/ribavirin-
(RBV)] were randomly assigned to vaccine (V:23), Peg-
IFNa2a-180-ug/qw and ribavirin 1000–1200-mg/qd for
48 weeks (P/R:25), or their combination (P/R + V:30).
Vaccine (100 lg/0.5 mL) was administered intramuscu-
larly at week 0-4-8-12-24-28-32-36. Neutralizing of bind-
ing (NOB) antibodies and lymphocyte proliferation assay
(LPA) for E1E2-specific-CD4 + T cells were performed at
week 0-12-16-48. Viral kinetics were analysed up to week
16. The vaccine was safe, and a sustained virological
response (SVR) was achieved in 4 P/R + V and 2 P/R
patients. Higher SVR rates were observed in prior relapsers
(P/R + V = 27.3%; P/R = 12.5%). Higher NOB titres and
LPA indexes were found at week 12 and 16 in P/R + V
as compared to P/R patients (P = 0.023 and 0.025,
P = 0.019 and <0.001, respectively). Among the 22
patients with the strongest direct antiviral effects of IFN
(e ≥ 0.800), those treated with P/R + V (10) reached lower
HCV-RNA levels (P = 0.026) at week 16. HCV E1E2MF59
vaccine in combination with Peg-IFNa2a + RBV was safe
and elicited E1E2 neutralizing antibodies and specific
CD4 + T cell proliferation. Upon early response to IFN, vac-
cinations were associated with an enhanced second phase
viral load decline. These results prompt phase II trials in
combination with new antiviral therapies.
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INTRODUCTION
Hepatitis C virus (HCV) is an enveloped virus of the flavi-
viridae family which contains a single stranded plus-sense
RNA genome with a single open reading frame [1]. The
polyprotein is cleaved by host and viral proteases to pro-
duce structural proteins (core and envelope glycoproteins
E1 and E2) and nonstructural (NS) components, among
which NS3 (serine protease and RNA helicase), NS5A and
NS5B (RNA-dependent RNA polymerase) represent the
major targets of the recently developed direct acting antivi-
rals (DAAs) [2–7].
Approximately 75% of acute infections become chronic,
and 20% of these progress to cirrhosis [8,9], making HCV
the most common viral disease in patients undergoing liver
transplantation [10]. Due to the complex mechanism of
HCV entry and the high variability of the E2 protein, the
development of an effective vaccine against HCV is still
underway. In the chimpanzee model, an adjuvanted proto-
type vaccine containing E1E2 envelope proteins was
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shown able to modify the natural course of the infection
[11,12]. Animals which developed high antibody titres
were protected against acute infection following homolo-
gous virus challenge and those with low anti-E1E2 anti-
body titres showed a significantly higher rate of viral
clearance as compared to nonvaccinated controls [11,12].
Interestingly, protection against chronic evolution was not
strongly correlated with the anti-E1E2 antibody titres, sug-
gesting an immune control mediated by the combination
of humoral and CD4 + T helper responses to E1E2 [13].
Despite the high rate of sustained virological response
(SVR) obtained by the combination of DAAs with Pegylat-
ed interferons (Peg-IFN) and ribavirin (RBV) in na€ıve geno-
type one patients [14], retreatment with currently
available triple therapy in prior partial or null responders
to Peg-IFN/RBV does not warrant the same chances of
SVR [15]. Indeed, in patients with insufficient response to
IFN, the initial rapid antiviral effect of the DAAs is neutral-
ized by the emergence of viral quasi-species with various
degree of resistance responsible for treatment failure. Viral
dynamics studies showed that whenever the block of HCV
production is not complete, the immune-mediated clear-
ance of the infected cells and virus infectivity become
major determinants of the treatment outcome [16,17].
Recently, the E1-E2 HCV vaccine candidate was shown
to be safe and generally well tolerated in the first clinical
trial in healthy volunteers [18]. Based on the hypothesis
that the humoral and cellular responses observed in nonin-
fected individuals could contribute to HCV clearance in
chronic patients, we performed a phase Ib trial aimed to
assess the safety of this vaccine and to test whether the
above responses could be elicited during the antiviral
treatment in chronic hepatitis C patients.
PATIENTS AND METHODS
Study design and conduct
This phase Ib open-label, randomized, multicentre, active-
treatment-controlled study was aimed to evaluate safety,
tolerability, viral kinetics and pattern of immune response
to HCV vaccine alone or combined with Peg-IFNa2a plus
ribavirin in patients chronically infected with HCV geno-
type 1a or 1b without signs of liver decompensation, portal
hypertension or hepatocellular carcinoma. The study was
approved by the phase I study commission of the Istituto
Superiore della Sanita of the Italian Ministry of Health and
from the central (Milano) and local Ethical Committees
(Bologna, Palermo, Pisa, Roma and Napoli) of the partici-
pant centres. A written informed consent was obtained
prior to any study procedure. Inclusion criteria required
that patients who failed treatment could be classified
according to the prior antiviral response as nonresponders
(NR <2 log HCV-RNA decline at week 12), partial respond-
ers (PR >2 log HCV-RNA decline at week 12 but detectable
HCV-RNA at week 24) or relapsers (REL = undetectable
HCV-RNA at the end of therapy not maintained thereaf-
ter). Eligible subjects stratified for their prior antiviral
response were randomized separately within each study
centre in a 1:1:1 ratio to receive: Group 1 (V) eight
100 lg doses of HCV E1E2MF59 vaccine (0.5 mL total vol-
ume) by intramuscular (deltoid) injections at week 0 (base-
line), 4, 8, 12, 24, 28, 32, 36; Group 2 (P/R): Peg-IFNa2a
180 lg weekly by subcutaneous injections and ribavirin
1000 mg (weight <75 kg) or 1200 mg (weight ≥75 kg)
per os bid for 48 weeks and Group 3 (P/R + V): P/R
combined with HCV E1E2MF59 vaccine as in Group 1.
At each study visit (screening, day: 0, 2 and 4, week: 1,
2, 3, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48 dur-
ing therapy, week: 1, 2, 4, 8, 12 and 24 after therapy),
blood samples were obtained for haematology, biochemis-
try, serology and (auto) immunology according to the
protocol. Peg-IFNa2a and ribavirin in Groups 2 and 3 were
discontinued in absence of EVR (week 12 HCV-RNA
decline from baseline <2 log) or in presence of detectable
HCV-RNA at week 24.
Assays
Alanine aminotransferase (ALT) and HCV-RNA serum lev-
els were measured at each study visit during treatment
and follow-up. Quantification of HCV-RNA for viral kinetics
was obtained by Roche Cobas Taqman assay (dynamic
range: 15–70 000 000 IU/mL) testing all frozen sera
(80 °C) from one patient in a single run at the central-
ized reference laboratory (Hepatology Unit – University
Hospital of Pisa).
The presence HCV antibodies with potential neutralizing
activity was investigated by the NOB assay that estimates
by cytofluorimetry the binding of serum gamma-globulins
to human cells coated with HCV envelope glycoprotein 2
(E2) [19]. The E2 antigen employed in this binding assay
was produced by the same system and purified in the same
manner as the antigen used for immunization. Sera were
tested at baseline, week 12, 16 and 48. A CD4 T cell lym-
phocyte proliferation assay (LPA) for E1E2-specific CD4+ T
cells was performed at the same time points in a subgroup
of Group 2 and 3 patients using a 3H thymidine incorpo-
ration assay [18]. CHO expressed HIV-gp120 and phytohe-
magglutinin (PHA) were used as negative and positive
controls, respectively. The results were expressed as stimu-
lation index (S.I.), the mean counts per minute (cpm) of
duplicate stimulated cell cultures divided by mean cpm of
duplicate unstimulated cell cultures. Stimulation index
corresponding at value one is the lower limit of LPA.
Viral kinetics model
To analyse individual viral and infected cell dynamics, we
applied a physic–mathematical model that fits both
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HCV-RNA and ALT declines during the first month of ther-
apy [16]. A detailed explanation of the method used to
compute parameters is available online (http://www.
nature.com/clpt/journal/v84/n2/extref/clpt200821x1.doc)
as supporting information of our previous publication [20].
Statistical analysis
The distribution of the variables according to treatment and
outcome was analysed using corrected chi-square for quali-
tative categories. Analysis of variance (ANOVA), Mann–
Whitney U-test or Kruskal–Wallis tests were used for the
quantitative variables. All the other tests were default
parameters of the statistical software package SPSS (version
19.0, SPSS Inc., Chicago, IL, USA). The associations found
were considered statistically significant for P value <0.05.
RESULTS
Safety
Overall, 78 patients were enrolled in this study from Janu-
ary 2005 to June 2008: 23 were randomized to receive
the vaccine alone (Group 1), 25 to P/R (Group 2) and 30
to P/R + V (Group 3). Serious adverse events (SAE)
occurred in four patients. Colon cancer and hepatocellular
carcinoma were diagnosed after 4 and 12 weeks of ther-
apy, respectively, in two Group 3 patients. Both SAEs were
judged not related to the therapy, and patients were with-
drawn from the study to start appropriate treatments. Two
patients had pneumonia, one during the screening period,
the other after 9 months of Peg-IFN/RBV therapy and
seven vaccine injections. Complete resolution was obtained
after 2 weeks by antibiotic treatment in both patients. In
the latter, the SAE was considered possibly related to
Peg-IFN and not to the vaccine by site investigators and
medical monitor. During the 72-week study period, the
prevalence of nonserious adverse events (percentage of vis-
its with at least one AE reported) was similar in patients
who received P/R (73%) or P/R + V (78%) and lower
(35%) in those who received vaccine alone. Most
frequently reported symptoms across all vaccinations
included mild or moderate fever, discomfort, headache,
myalgia and pain/tenderness at the vaccination site. Other
typical local reactions (redness, pain or tenderness and
warmth) and systemic reactions (fever, malaise, myalgia,
arthralgia, headache, nausea and fatigue) were reported
and attributed to Peg-IFN or RBV therapy. None of the
patients treated with the vaccine alone or in combination
with P/R had the induction of autoimmune phenomena.
Treatment response
Response to prior and investigational treatments is summa-
rized in Table 1. None of the 23 patients who received HCV
E1E2MF59 vaccine alone cleared HCV, nor showed >1 log
HCV-RNA decline at week 24 and 48. Peg-IFN/RBV antivi-
ral treatment was completed according to the protocol in
24/25 Group 2 patients (1 drop out) and in 24/30 Group 3
patients (2 SAE, 4 did not take the vaccine for a procedural
error). Two (8%) patients treated with P/R (1 prior NR and
1 REL) and 4 (16%) patients treated with P/R + V (1 prior
NR and 3 REL) became SVR. The rate of SVR among patients
with a previous relapse was higher with P/R + V (27.3%)
than with P/R alone (12.5%), although the difference did
not reach statistical significance (P = 0.173).
Immune response
At baseline, the titre of anti-HCV E1E2 antibodies measured
by the NOB assay, although higher in P/R + V
(7263  11130) than in P/R (3362  5764) and V
(3342  4672) patients, was not significantly different
between the three arms (ANOVA, P = 0.417). Considering
only P/R and P/R + V patients, the median titre of the NOB
assay at baseline was significantly higher in SVR (5545;
range: 460–16200) and REL (2430; range: 130–37500)
than in PR (440; range: 130–18320) and NR (260; range:
90–5930) (Kruskal–Wallis: P = 0.029). During therapy,
the NOB titres decreased in P/R but not in P/R + V-treated
patients, reaching significantly lower levels at week 12
(2172  3109 vs 8979  13228, P = 0.023) and 16
Table 1 Response to prior and investigational treatments
Prior therapy
outcome
Patients by study
treatment Per protocol response in patients who completed the antiviral therapy
V P/R P/R + V P/R EVR (%) SVR (%) P/R + V EVR (%) SVR (%)
NR 11 11 9 10 6 (60%) 1 (10%) 9 3 (33%) 1 (11%)
PR 5 6 5 6 4 (66%) 0 4 3 (75%) 0
REL 7 8 12 8 7 (87.5%) 1 (12.5%) 11 9 (82%) 3 (27%)
Total 23 25 26 24 17 (71%) 2 (8%) 24 15 (63%) 4 (17%)
EVR, early virological response (undetectable or HCV-RNA decline ≥2 Log from baseline at week 12). SVR, sustained
virological response.
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(2005  2100 vs 7578  11051, P = 0.025). At the end
of therapy (week 48), the NOB titres decreased also in
P/R + V patients to levels not significantly different from
those of P/R-treated patients (Table 2). In vaccine alone-
treated patients, the NOB titres did not show significant
changes. The LPA index increased to significantly higher
Table 2 Neutralizing antibodies by quantitative neutralization of binding (NOB) assay and specific E1E2-CD4 + T cells by
lymphocyte proliferation assay (LPA) during therapy
Group of patients
(number)
Basal NOB
titre
Week 12
NOB titre
Week 16
NOB titre
Week 48
NOB titre
Basal
LPA index
Week 12
LPA index
Week 16
LPA Index
V (21)
Mean 3362 2541 3602 na na na na
SD 5764 2476 4524 na na na na
P/R (22)
Mean 3342 2172 2005 1895 1.32 1.12 2.43
SD 4672 3109 2100 2207 1.06 0.79 5.02
P/R + V (22)
Mean 7263 8979 7578 3710 1.21 24.0 34.1
SD 11130 13228 11051 4788 0.54 40.7 33.9
P/R vs P/R + V*
P value 0.135 0.023 0.025 0.189 0.701 0.019 <0.001
na, not available; *ANOVA.
Bold values indicate significant values (P < 0.05).
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Fig. 1 Kinetics of anti-HCV immune responses. Panels a and b show mean  SD NOB antibody titre and median with
range lymphocyte proliferation assay (LPA) stimulation index (S.I.) at baseline (day 0), week 12 (day 84), 16 (day 112)
and 48 (day 336) in 4 SVR and in 10 REL patients treated with P/R + V. Panels c and d show mean  SD NOB antibody
titre and median with range lymphocyte proliferation assay (LPA) stimulation index (S.I.) at baseline (day 0), week 12
(day 84), 16 (day 112) and 48 (day 336) in 2 SVR and in 10 REL patients treated with P/R.
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levels in P/R + V as compared to P/R alone-treated patients
at week 12 (24.0  40.7 vs 1.12  0.79, P = 0.019) and
16 (34.1  33.9 vs 2.43  5.02, P < 0.001) (Table 2).
The kinetics of NOB titre and LPA index during P/R + V
therapy showed different profiles in SVR as compared to
REL patients (Fig. 1); the difference, however, did not reach
statistical significance due to the low number of cases and
the high degree of the individual variability. On the con-
trary, in P/R-treated patients, no changes in NOB titres and
LPA index were observed (Fig. 1).
Viral dynamics
Viral kinetics could be analysed by the model in 44 patients
who completed the protocol, 22 (91.7%) treated with P/R
and in 22 (91.7%) treated with P/R + V (Table 3). Therapy
outcome was significantly correlated with the values of
the parameters e (P = 0.010), p (P < 0.001) and c
(P = 0.001), describing the strength of the antiviral effects
of Peg-IFN/RBV therapy during the biphasic decline in the
viral load, and with the end of therapy estimates of HCV
infected cells Ieot (P = 0.006) and of residual viral load
Veot (P = 0.001). Given the major role played by the direct
antiviral activity of Peg-IFN/RBV therapy, the potential
impact of the first course of vaccinations (week 0-4-8-12)
was analysed in patients with comparable effectiveness of
Peg-IFN/RBV therapy. Dichotomization of Group 2 and 3
patients by the median value of e (0.800) showed that in
22 patients (12 P/R and 10 P/R + V) with e ≥0.800, the
log HCV-RNA levels at week 16 were significantly lower in
those treated with P/R + V than in those treated with P/R
alone (Mann–Whitney U-test, P = 0.026). The kinetics of
the viral load decline with the changes in the NOB titre and
of the LPA index in these patients is shown in Fig. 2.
Characterization of the IL28B polymorphism showed
that the favourable CC genotype was present in only three
patients per arm, and in none of the SVR patients (3 CT
and 3 TT). In CC patients, there was a trend towards a
more effective inhibition of viral replication (e median
value: CC = 0.945, CT = 0.880, TT = 0.680; P = 0.073,
Kruskal–Wallis).
DISCUSSION
The results of the phase Ib study of the candidate HCV
E1E2 vaccine adjuvanted with MF59 in chronic hepatitis C
Table 3 Baseline variables and model-computed parameters describing the dynamics of HCV infection during therapy
according to treatment arm and response to antiviral therapy
Group of
patients (n.)
Basal
ALT U/L
Basal
HCV RNA
Log IU/mL e p c d0
Log
Ieot
Log
Veot
P/R (22)
Mean 82.7 6.3 0.6611 0.1064 0.5562 0.0421 5.81 4.61
SD 50.2 0.6 0.5454 0.0934 1.0345 0.0337 6.17 5.14
P/R + V (22)
Mean 98.7 6.5 0.7153 0.0924 0.5306 0.0346 5.21 4.14
SD 57.0 0.5 0.2667 0.0602 1.6283 0.0229 5.47 4.58
P value* 0.25 0.18 0.77 0.53 0.99 0.44 0.15 0.40
NR (14)
Median 96 6.3 0.5950 0.0241 0.7400 0.0144 5.53 4.34
Range 52–185 5.2–6.9 0.09–0.94 0.004–0.07 0.023–8.07 0.003–0.068 3.3–6.6 2.6–5.8
PR (9)
Median 61 6.9 0.7700 0.0691 0.0096 0.0399 3.11 1.64
Range 46–226 6.0–7.6 0.48–0.95 0.040–0.24 3104–0.93 0.005–0.075 2.0–6.1 0.3–3.6
REL (15)
Median 65 6.4 0.9050 0.1200 0.0032 0.0351 3.44 0.45
Range 35–234 5.2–7.2 0.52–0.999 0.064–0.23 2105–0.98 0.001–0.14 0.3–6.7 3.4–3.0
SVR (6)
Median 77.5 6.3 0.7404 0.1910 0.0002 0.0629 2.47 0.88
Range 38–220 5.5–7.4 1.58–0.94 0.085–0.44 4106–0.81 0.007–0.10 1.7–5.5 4.1–2.4
P value† 0.35 0.083 0.010 <0.001 0.001 0.080 0.006 0.001
e = effectiveness of IFN in blocking viral production; p = 2nd phase HCV-RNA decay rate constant; c = asymptotic value of
the viral production coefficient during therapy; d0 = infected cell clearance rate constant; I0 = computed infected cell
number at baseline; Ieot = computed infected cell number at the end of therapy; Veot = computed viral load at the end of
therapy; * ANOVA; † Kruskal–Wallis (comparison between the four categories).
Bold values indicate significant values (P < 0.05).
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patients who failed previous interferon and ribavirin
therapy showed that HCV E1E2 vaccine is safe either alone
or in combination with peginterferon-alpha-2a and ribavi-
rin. Only mild–moderate local and/or systemic reactions
related to the vaccine injections were reported. Given alone
the vaccine did not induce significant changes in viral
load, however, the combination of Peg-IFN/RBV (P/R) with
the vaccine (V) was associated with a higher SVR rate
(17% vs 8%). The SVR rate was influenced by the type of
response to the previous treatment, being higher in prior
relapsers (27.3% vs 12.5%). Although the outcome was
twice as better in P/R + V than in P/R alone, this differ-
ence was not statistically significant (corrected chi-square:
P = 0.173), possibly because of the low number of patients
enrolled to study the safety and not the efficacy of HCV-
E1E2 vaccine. Interestingly, the immunological assays
showed relevant vaccine induced responses. he analysis of
a surrogate assay for neutralizing antibody (NOB) in the
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Fig. 2 Viral kinetics and anti-HCV immune responses. Panel a shows median log HCV-RNA (95% CI) decline during the
first 16 weeks (day 112) of therapy in 12 P/R and 10 P/R + V patients with higher and homogeneous block of virus
production (e ≥0.800). For undetectable HCV-RNA levels (<15 IU/mL), the attributed value of 5 IU/mL (0.70 log) was used
for computing the median value. Panel b shows mean  SD NOB antibody titre variations (fold change from baseline) at
week 12 and 16 in the same patients. Panel c shows mean  SD LPA stimulation index (S.I.) variations at week 12 and
16 in the same patients.
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overall cohort of patients receiving antiviral treatment
showed that baseline NOB titre positively correlates with
better outcomes. During therapy, NOB titres decreased in
P/R-treated patients but not in P/R + V, reaching a signifi-
cant difference between the two arms at week 12 and 16
(Table 2). In addition, HCV-specific CD4 responses signifi-
cantly increased in the P/R + V-treated patients (Table 2)
and reached the highest levels in SVR patients (Fig. 1).
The difference between SVR and REL patients was not
statistically significant, probably because of the high degree
of individual variability observed and the low number of
patients that could be studied. We can also hypothesize
that the variability of the responses might be related to the
abnormalities of the T cell functions found in chronically
infected patients [22]. Indeed, HCV was shown to induce a
state of T cell exhaustion that was attributed to a defective
activation of the dendritic cells [23–25], not present in all
patients [26].
Altogether these findings underlie the role of the specific
immune responses during therapy and are conceivable
with our model of viral dynamics [17,20,21], which simu-
lates the interplay between the virus and the immune sys-
tem during IFN/RBV therapy assuming that the reduction
in the infected cell number during therapy leads to a rela-
tive reduction in the CTL clearance activity. In turn, this
negative feedback may favour the persistence of infected
cells that explain hepatitis recurrence after therapy in
relapser patients. The new direct antiviral agents (DAAs)
block viral replication more efficiently than IFN; however,
they are not expected to enhance adaptive immune
responses. Thus, patients in whom these drugs are not
completely effective could benefit from the combination of
a therapeutic vaccine.
To analyse the potential additional effect of the HCV
E1E2 vaccine in patients with higher and homogeneous
block of virus production, the subgroup of 22 patients (12
P/R and 10 P/R + V) with e above the median value of
0.800 was analysed separately. Interestingly, the vaccine
combination brought viral load to significantly lower levels
at week 16, 4 weeks after the end of the first course of
vaccine injections. The faster decline in the viral load,
together with the evidence of a relative increase in NOB
titre and LPA index (Fig. 2), supports the hypothesis of a
potential effect of the vaccine in this subset of patients.
Therefore, from the analysis of viral dynamics, it is possible
to hypothesize that the increased titres of anti-HCV-E1E2
antibodies and the increased cellular responses observed in
P/R + V-treated patients may translate in a more efficient
control of the infection either by further reduction in target
cell infections and/or residual viral production.
Finally, not surprisingly, the analysis of the rs12979860
SNP upstream to the IL28B gene [27] showed that the
favourable CC allele was present in a small proportion
(13%) of our treatment experienced patients. The CC allele
was equally distributed in the two arms, and it was associ-
ated with a trend to a greater 1st phase direct antiviral
effectiveness of Peg-IFN/RBV, but not with SVR. Nowa-
days, DAAs warrant an improved inhibition of viral repli-
cation but still need combination with P/R to prevent
resistance. Our study let hypothesize that whenever IFN
free schedules will be available, HCV vaccines might
become a useful combination in a subgroup of patients to
replace the nonspecific immune modulation activity of IFN
with a more specific stimulation of anti-HCV adaptive
responses. These results prompt future studies with candi-
date HCV vaccines in combination with new DAAs in
difficult to treat patients.
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